دورية أكاديمية
The SNPs in pre-miRNA are related to the response of capecitabine-based therapy in advanced colon cancer patients.
| العنوان: | The SNPs in pre-miRNA are related to the response of capecitabine-based therapy in advanced colon cancer patients. |
|---|---|
| المؤلفون: | Mao Y; Department of Medical Oncology, Institute of Cancer, Affiliated Hospital of Jiangnan University and The Fourth People's Hospital of Wuxi, Wuxi 214062, China., Zou C; Center for Drug Metabolism and Pharmacokinetics, College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China.; Department of Orthopedics, Children's Hospital of Soochow University, Suzhou 215123, China., Meng F; Center for Drug Metabolism and Pharmacokinetics, College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China., Kong J; Center for Drug Metabolism and Pharmacokinetics, College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China., Wang W; Center for Drug Metabolism and Pharmacokinetics, College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China., Hua D; Department of Medical Oncology, Institute of Cancer, Affiliated Hospital of Jiangnan University and The Fourth People's Hospital of Wuxi, Wuxi 214062, China. |
| المصدر: | Oncotarget [Oncotarget] 2017 Dec 11; Vol. 9 (6), pp. 6793-6799. Date of Electronic Publication: 2017 Dec 11 (Print Publication: 2018). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Impact Journals Country of Publication: United States NLM ID: 101532965 Publication Model: eCollection Cited Medium: Internet ISSN: 1949-2553 (Electronic) Linking ISSN: 19492553 NLM ISO Abbreviation: Oncotarget Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Albany, N.Y. : Impact Journals |
| مستخلص: | The single nucleotide polymorphisms (SNPs) in the microRNA precursor (pre-miRNA) may modulate the posttranscriptional regulation of gene expression and explain individual sensitivity to chemotherapy. Here we investigated the correlation between 23 SNPs in the pre-miRNA and the efficacy of capecitabine-based chemotherapy in 274 advanced colon cancer patients. Statistical analysis indicated that much more patients with rs744591 A/C(48.03%), C/C (53.45%) or C allele (49.73%) responded to the chemotherapy than those with the A/A genotype (33.71%). The response rates of rs745666 G/C heterozygous patients (35.25%) and C allele carriers (39.69%) were apparently less than that of the G/G homozygous patients (56.25%). Moreover, three SNPs rs2114358, rs35770269, and rs73239138 were significantly associated with the occurrence of side effects of chemotherapy. The patients with rs2114358 C allele (OR = 2.016) or rs35770269 T allele (OR = 2.299) were much more prone to endure adverse events. However, the incidence of side effect was lower in the patients carrying rs73239138 A allele than those with G/G genotype (OR = 0.500). Our findings demonstrate that genetic variations in pre-miRNA may influence the efficacy of capecitabine-based chemotherapy in advanced colon cancer patients. Competing Interests: CONFLICTS OF INTEREST The authors declare that they have no conflicts of interest. |
| References: | Mol Cancer Res. 2008 Feb;6(2):212-21. (PMID: 18314482) Br J Dermatol. 2012 Oct;167(4):847-55. (PMID: 22540308) Nucl Med Biol. 2015 May;42(5):499-504. (PMID: 25682061) Am J Transl Res. 2015 Oct 15;7(10):2091-8. (PMID: 26692953) Clin Cancer Res. 2015 May 1;21(9):2038-44. (PMID: 25655103) IUBMB Life. 2014 May;66(5):371-7. (PMID: 24846313) Cancer Manag Res. 2011;3:79-89. (PMID: 21629830) Int J Clin Exp Med. 2015 Jan 15;8(1):714-21. (PMID: 25785048) BMC Cancer. 2014 Jul 21;14:529. (PMID: 25047087) Pharmacogenet Genomics. 2017 Aug;27(8):303-306. (PMID: 28628559) PLoS One. 2015 Mar 20;10(3):e0118905. (PMID: 25793711) Trends Mol Med. 2011 Aug;17(8):412-23. (PMID: 21652264) Carcinogenesis. 2016 Sep;37(9):852-7. (PMID: 27381831) CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32. (PMID: 26808342) PLoS One. 2012;7(10):e47454. (PMID: 23077621) Nat Rev Clin Oncol. 2017 Apr;14 (4):235-246. (PMID: 27922044) CA Cancer J Clin. 2015 Mar;65(2):87-108. (PMID: 25651787) Pharmacogenomics. 2009 Apr;10(4):639-53. (PMID: 19374519) Bull Cancer. 2017 Apr;104(4):311-320. (PMID: 28081866) FEBS Lett. 2013 May 2;587(9):1359-65. (PMID: 23507140) Cell. 2012 Apr 27;149(3):515-24. (PMID: 22541426) Pathol Oncol Res. 2017 Oct 4;:null. (PMID: 28980150) Int J Biol Sci. 2017 Aug 17;13(8):1038-1050. (PMID: 28924385) J Biol Chem. 2012 Jan 20;287(4):2509-19. (PMID: 22110125) Oncotarget. 2016 Nov 22;7(47):77764-77776. (PMID: 27780918) Carcinogenesis. 2015 Aug;36(8):867-75. (PMID: 25977444) BMC Cancer. 2014 Dec 03;14 :909. (PMID: 25472505) Tumour Biol. 2016 Jul;37(7):9411-22. (PMID: 26781873) Int J Cancer. 2016 Jun 1;138(11):2752-61. (PMID: 26804235) PLoS One. 2014 Mar 10;9(3):e91261. (PMID: 24614921) Cell. 2009 Jan 23;136(2):215-33. (PMID: 19167326) Int Immunopharmacol. 2016 Oct;39:41-47. (PMID: 27409728) Pharmacogenet Genomics. 2011 Apr;21(4):237-42. (PMID: 20601926) |
| فهرسة مساهمة: | Keywords: capecitabine; colon cancer; microRNA; polymorphism |
| تواريخ الأحداث: | Date Created: 20180223 Latest Revision: 20220331 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC5805515 |
| DOI: | 10.18632/oncotarget.23190 |
| PMID: | 29467929 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1949-2553 |
|---|---|
| DOI: | 10.18632/oncotarget.23190 |